NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule [Yahoo! Finance]
NeuroSense Therapeutics Ltd. (NRSN)
Company Research
Source: Yahoo! Finance
neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing. To regain compliance with the Rule, the Company's ordinary shares were required to maintain a minimum closing bid price of or more for at least 10 consecutive business days, which was achieved on February 6, 2024 . Therefore, the Nasdaq Listing Qualifications Staff considers the prior bid price deficiency matter now closed. NeuroSense's CEO, Alon Ben-Noon said, "Regaining compliance with the Nasdaq minimum bid price listing requirement is an important event as we continue to focus on the advancement of PrimeC following the recently announced positive top-line results from the Phase 2b PARADIGM trial. We are looking forward to reporting results from our collaboration with Biogen in the coming weeks, evalu
Show less
Read more
Impact Snapshot
Event Time:
NRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRSN alerts
High impacting NeuroSense Therapeutics Ltd. news events
Weekly update
A roundup of the hottest topics
NRSN
News
- NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
- NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseasePR Newswire
- NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingPR Newswire
- NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 [Yahoo! Finance]Yahoo! Finance
NRSN
Sec Filings
- 4/25/24 - Form D
- 4/12/24 - Form 424B5
- 4/12/24 - Form 6-K
- NRSN's page on the SEC website